Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial of Sebetralstat in Healthy Japanese, Chinese, and White Adults

Next Previous
X
Search
Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial of Sebetralstat in Healthy Japanese, Chinese, and White Adults

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sebetralstat (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics

    • Most Recent Events

    • 14 Jun 2023 New trial record
    • 12 Jun 2023 According to a KalVista Pharmaceuticals media release, data from this trial is supporting the continued global expansion of the ongoing KONFIDENT phase 3 trial.
    • 12 Jun 2023 According to a KalVista Pharmaceuticals media release, results from this trial were presented at the 2023 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI) 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top